TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Approvals & Labels

Ipsen lands FDA approval, queues race with Intercept Pharmaceuticals
Small molecule, primary biliary cholangitis - Read more

THE GOOD
Business Development

Cyrus Biotechnology spins out Levitate Bio
Software, biomolecular modelling, protein simulations - Read more

THE GOOD
Clinical Trials

ProKidney has positive Ph2 data + operational updates
Autologous cell therapy, chronic kidney disease - Read more

Merry Life Biomedical’s IND gets FDA ok, Ph1 trial to commence
Small molecule, Alzheimer’s - Read more

THE GOOD
Company Launches

New Challenger Approaching: Syntis Bio launches to take on weight-loss heavy hitters
Polymer, obesity, weight-loss - Read more

THE GOOD
Fundraises

Adcytherix €30M ($32.2M) Seed raise
Antibody-drug conjugates, cancer - Read more

Moleculant $26M overprescribed Series A
Functional profiling, spatial mapping, cell-cell communications - Read more

Bright Peak Therapeutics $90M Series C
Immunoconjugate, “antibody drug conjugate-like“, cancer, solid tumour - Read more

ProKidney proposal $125M public offering
Autologous cell therapy, chronic kidney disease - Read more

THE GOOD
Lawsuits

GSK notches another win in Zantac suits
Small molecule, heartburn, cancer - Read more

THE GOOD
Mergers & Acquisitions

Stada Arzneimittel allegedly courted by PE firm; current owners aiming for €11B ($11.8B) cash-out
Consumer health, generics, specialty pharma - Read more

SPONSORED
Your small batch will impress everyone!

Want to impress with a batch that meets the highest quality standards?

Get ready to just focus on your product as we will release it in only 4 months! ⚡️

Unlock the potential of your small batch with White Raven! 🧪

Learn NOW how you can impress everyone with your small batch!

Discover our dedication to the production of small batches with solutions that are customized to suit your unique product’s needs. 

THE GOOD
Opinions

AstraZeneca secures 2nd place after Roche amongst cancer patient groups
Patient opinions, survey, cancer - Read more

THE GOOD
Partnerships

Stada’s expand licensing pact with Alvotech, lands European rights for biosimilar to an Amgen blockbuster
Monoclonal antibody, osteoporosis, cancer - Read more

THE GOOD
Product Launches

Apple Watch health metric software gets an upgrade
Consumer health, medical device - Read more

THE GOOD
Strategic Plans

Take a break; Pfizer’s CEO says they’re taking a time-out from M&A after a spate of high-$$$ deals
Big Pharma, mergers & acquisitions strategy - Read more

Charles River Laboratories announces development work on another animal-testing alternative
Animal-free testing, inhalation toxicity - Read more 

THE BAD
Clinical Trials

Sage delivers meh Huntington’s results; analysts unimpressed
Small molecule, Huntington’s disease - Read more

THE BAD
Market Reports

Boston-based biotechs need the opposite of layoffs - they need more people
Worker shortage - Read more

THE BAD
Patient Access

Lots of US patients are paying out-of-pocket for Eli Lilly’s Zepbound
GLP-1, obesity, weight-loss - Read more

THE BAD
Politics & Policy

Current House bill indicates FDA funding would stay flat - Read more [Paywall]

THE BAD
Strategic Plans

Alphabet’s Verily pivots again - from “defeat Mother Nature” to unoriginal ideas
Digital health, telehealth, GLP-1, diabetes, hypertension - Read more [Paywall]

THE UGLY
Criminal Acts

How Mallinckrodt sold more opioids than anyone - by shaping scientific and medical opinion
Opioids, addiction - Read more

THE UGLY
Lawsuits

Gilead’s proposed $40M settlement in HIV drug delay suits
HIV, antiviral - Read more 

New Jersey federal judge says Teva Pharmaceuticals’ inhaler patents are “improperly listed”
Small molecule, inhaler, asthma - Read more [Paywall]

THE UGLY
Politics & Policy

J&J’s Stelara is “unaffordable”, according to Colorado’s Prescription Drug Affordability Review Board (PDAB)
Monoclonal antibody, autoimmune, drug pricing - Read more

Novo Nordisk might get subpoenaed over Ozempic & Wegovy prices
GLP-1, diabetes, obesity, drug pricing - Read more [Paywall]

THE UGLY
Research

Cancer incidence rates might be growing in successive social generations; study
Cancer diagnosis, Gen X - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 300+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.